KIORA PHARMACEUTICALS INC Cash Flow Statement
KPRX|8 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
KIORA PHARMACEUTICALS INC generated $9M in operating cash flow and $9M in free cash flow in FY2025. Free cash flow margin was 53.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -5.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $3.6M | -$12.5M | -$8.1M | -$7.1M | -$10.8M | -$13.2M | -$13.3M | -$8.4M |
| Depreciation & Amortization | $19.2K | $51.8K | $33.4K | $51.7K | $38.5K | $19.3K | $5.2K | $1.3K |
| Operating Cash Flow | $8.6M | -$9.6M | -$7.3M | -$8.2M | -$10.8M | -$6.5M | -$8.4M | -$4.5M |
| Capital Expenditures | $6.3K | $0 | $20.1K | $0 | $20.0K | $37.0K | $0 | - |
| Free Cash Flow | $8.6M | -$9.6M | -$7.3M | -$8.2M | -$10.9M | -$6.5M | -$8.4M | - |
| FCF Margin | 53.4% | - | -60844.6% | -303.6% | -657.4% | -1596.4% | -1257.1% | - |